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Background/aim: In this study, we aim to investigate the efficacy of convalescent plasma (CP) according to blood groups (BGs) in the
treatment of critically ill patients diagnosed with COVID-19.
Materials and methods: Twenty-eight critically ill and laboratory-confirmed COVID-19 patients who were admitted to the intensive
care unit (ICU) of Sakarya University, Medical Faculty were included in the study. Patients were divided into 2 groups: patients who
received anti-A antibody (Ab) containing CP (BG O and B) and those who did not receive CP containing anti-A Ab (BG A and AB).
Results: Among the 28 patients, 13 patients received anti-A Ab containing CP (BG; B: 6, O: 7) and 15 patients did not receive anti-A Ab
CP (BG; A: 13, AB: 2). Duration in ICU, the rates of mechanical ventilation (MV) support and vasopressor support, the case fatality rate,
and the discharge rate were lower in patients who received CP containing anti-A Ab than not containing anti-A Ab CP. However, only
the difference in the rate of MV support achieved statistically significance (P = 0.04)
Conclusion: In our study, it was observed that the efficiency of CP without anti-A antibody was lower than that of plasma containing
anti-A antibody, although it was not statistically significant. This result is thought to be due to the anti-A antibody’s ability to block the
ACE2 receptor. We believe that this hypothesis should be investigated in controlled studies with higher patient numbers.
Key words: Blood groups, COVID-19, convalescent plasma

1. Introduction
The new type of Coronavirus (CoV) first appeared in
Wuhan, China in December 2019 with a cluster of unknown
and unidentified pneumonia [1]. After genetic analysis of
the virus, it was understood that these pneumonia cases
were caused by the 2019 Novel CoV (2019-nCoV), which
was later called SARS-CoV-2 [2]. The disease caused by
2019-nCoV was officially named COVID-19 and was
declared as a pandemic by the World Health Organization
(WHO) on March 11, 2020.
Convalescent Plasma (CP) is a passive antibody
(Ab) treatment that was used during the 2003 SARS,
2009 H1N1, 2012 MERS, and 2013 Ebola outbreaks
and has been shown to be effective [3,4]. Based on all

of these experiences, the United States Food and Drug
Administration (FDA) approved CP in the treatment
of critically ill COVID-19 patients on March 24, 20201.
However, there are some issues that need to be clearly
determined to optimize CP treatment, such as the efficacy
and safety of the treatment, optimum volume of CP, the
number of transfusions, the interval between transfusions,
the optimum titer of neutralizing Ab, efficacy of pathogen
inactivation processes, and the optimal donation time.
In the pathogenesis, the entry gate of SARS-CoV-2
has been shown to be angiotensin-converting enzyme 2
(ACE2) receptors. SARS-CoV-2 binds to ACE2 receptors
with the S glycoprotein on its surface and initiates the
immune response [5,6]. A recent study has reported

FDA (2020). Investigational covid‐19 convalescent plasma—emergency INDs [online]. Website https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ideprocess-cber/investigational-covid-19-convalescent-plasma-emergency-inds [accessed 11 May 2020].
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a structural similarity between the receptor-binding
domains of SARS-CoV and SARS-CoV-2 [7]. Researchers
revealed that natural plasma anti-A antibodies inhibited
the SARS-CoV S protein/ACE2-dependent adhesion
to ACE2-expressing cells [8]. Since SARS-CoV2 uses
the same receptor as SARS-CoV, anti-A isoagglutinins
are expected to have similar effects against SARS-CoV2
[9]. Anti-A natural isoagglutinin can be also found in
CP donated from O and B blood group (BG) donors.
Therefore, it can be inferred that the treatment results of O
and B BG patients may be better as a result of the natural
presence of anti-A antibodies and administration of extra
in CP. In this study, we aim to investigate the efficacy of CP
according to BGs in the treatment of critically ill patients
diagnosed with COVID-19.

and, additionally, Turkish Health Ministry approval was
also obtained on June 12th, 2020 for this study, as required.
2.2. Statistical analysis
IBM SPSS v26 software (IBM Corp., Armonk, NY,
USA) was used for analysis. Descriptive statistics were
implemented to summarize data. Variables assessed for
normal distribution with graphics and the Shapiro–Wilk
test. An independent t-test was applied to assess age and
ICU duration between groups Categorical data were
presented as number and percentages, and numerical data
were presented as mean ± standard deviation. Differences
between categorical variables were analyzed with the
chi-square test, and parametric continuous variables
were analyzed with a one-way ANOVA test. A two-sided
P-value ≤0.05 was considered statistically significant.

2. Materials and methods
2.1. Patient population
Approximately 28 critically ill and laboratory-confirmed
COVID-19 patients who were admitted to the intensive
care unit (ICU) of Sakarya University, Medical Faculty
between March 11, 2020 and June 02, 2020 and who
received a CP transfusion in addition to antiviral therapy
were included in the study. All patients were detected to
be SARS-CoV-2 RNA positive by nasal and pharyngeal
swab samples using a SARS-CoV-2 nucleic acid detection
kit (Genesig Real-Time, Primer Design, UK). Critical
COVID-19 was defined as exhibiting the presence of
respiratory failure, septic shock, and/or multiple organ
dysfunctions1. Therapeutic apheresis centers licensed by
the Republic of Turkey’s Ministry of Health and the Turkish
Red Crescent carried out activities to obtain CP from
donors. Donor assessments were performed according to
the Republic of Turkey’s Ministry of Health and Donor
Eligibility Criteria for COVID-19 Convalescent Plasma2. In
addition to nucleic acid amplification tests, all donors were
serologically screened for HBsAg, anti-HCV, anti-HIV 1-2
and, anti-Syphilis Ab. The titer of neutralizing Ab was
not routinely performed. CP was collected by apheresis.
Approximately 200–600 cc of plasma was collected with
apheresis devices depending on the total blood volume
of the donor. Plasma components were labeled using the
ISBT128 coding system and stored at or below –18/25 C° in
storage cabinets. Pathogen inactivation processes were not
routinely performed. Patients were divided into 2 groups
as anti-A Ab containing CP received patients (BG O and
B) and those who received CP not containing anti-A Ab
(BG A and AB). Clearance of SARS-CoV-2 was defined as
at least 2 consecutive negative RT-PCR test results.
Local Ethical Committee approval was obtained from
Sakarya University, numbered 71522473/050.01.04/342

3. Results
Among the 28 patients included in this study, 13 patients
received anti-A Ab containing CP (BG; B: 6, O: 7), and 15
patients received CP not containing anti-A Ab ( BG; A: 13,
AB: 2). The characteristics of the patients are given in Table
1. All patients received favipiravir, lopinavir/ritonavir,
and hydroxychloroquine. Eleven patients received 3 CP
transfusions (600 cc), 10 patients received 2 CP transfusions
(400 cc), and 7 patients received 1 CP transfusion (200 cc).
When we compared the outcome of patients who received
CP containing anti-A Ab to the outcome of patients who
received CP not containing anti-A Ab, the duration in
the ICU was shorter. In addition, the rates of mechanical
ventilation (MV) support and vasopressor (VP) support,
the case fatality rate (CFR), and the discharge rate were
lower in patients who received CP containing anti-A Ab.
However, only the difference in the rate of MV support
achieved statistical significance (P = 0.04) (Table 2). When
BGs were analyzed separately, no statistically significant
difference was observed regarding the duration in ICU,
the rates of MV support and VP support, and the CFR and
discharge rates.
4. Discussion
Prediction of ABO BGs has been previously investigated,
especially in viral infections such as HIV, Hepatitis B, and
Severe Acute Respiratory Syndrome (SARS) [10]. In a
previous study, anti-A Ab was shown to neutralize HIV
produced by lymphocytes from blood group A donors
only [11]. Similar to the reports about HIV, researchers
demonstrated that the measles virus was neutralized by
natural anti-A Ab in a complement-dependent manner
[12]. If natural anti-A or -B serum antibodies provide
protection, it is expected that during an outbreak, BG O
individuals should experience a lower risk of infection

Turkish Ministry of Health (2020). COVID-19 İmmün (Konvalesan) Plazma Tedarik ve Klinik Kullanım Rehberi [online]. Website https://dosyamerkez.
saglik.gov.tr/Eklenti/37163,covid-19-immun-plazma-rehberi-12-nisan-2020-sonv1-ti-neopdfpdf.pdf?0 [accessed 17 April 2020].
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Table 1. Characteristics of patients.
A+ AB
(n = 15)

Table 2. Outcome of patients.
B+O
(n = 13)

P value

Characteristics

A and AB
(n = 15)

B and O
(n = 13)

ICU stay (mean±SD) 15.3 ± 7.7

12 ± 9.8

0.62

MV support

14 (93.3%)

8 (61.5%)

0.04*

Sex
Male: n (%)
Female: n (%)

VP support

12 (80%)

6 (46.2%)

0.06

9 (60%)
6 (40%)

11 (84.6%)
0.22
2 (15.4%)

Discharge rate

4 (26.7%)

6 (46.2%)

0.28

Age, years (mean±SD)

64.6 ± 12.3 62.6 ± 9.8

0.75

CFR

9 (60%)

7 (53.8%)

0.74

Comorbidity: n (%)
Diabetes mellitus
Hypertension
Cardiovascular diseases
Respiratory system diseases
Chronic renal diseases
Cerebrovascular diseases
Cancer

7 (46.7%)
9 (60%)
3 (20%)
1 (6.7%)
1 (6.7%)
0
1 (6.7%)

N/A

SD: standard deviation; N/A: not applicable.

than non-BG O individuals. During the outbreak of
SARS, the O BG group was reported as having a lower
risk of being infected by SARS-CoV than subjects from
other BG groups [8,13]. SARS-CoV infects cells such as
pneumocytes, enterocytes of the small intestine, as well
cells of the kidney distal tubular epithelium—all cell types
known to be able to synthesize ABH antigens [14,15,].
There are studies in the literature reporting that there is a
structural similarity between the receptor binding domains
of SARS-CoV and SARS-CoV-2. The main mechanism
of SARS-CoV-2 is that it binds to human ACE2 surface
receptors with the S glycoprotein on its surface and enters
the cell and initiates immune mechanisms [16].
Anti-A Ab was shown to inhibit the SARS-CoV S
protein/ACE2-dependent adhesion. In addition to the
blocking of virus attachment to its receptor, natural
antibodies can block entry or opsonize viral particles
leading to complement-mediated neutralization [17]. A
recent publication showed that the odds ratio for acquiring
COVID-19 is higher in blood group A than in blood group
O [18]. Elderly males are known to experience reductions
in isoagglutinin titers, and previous studies have shown
that COVID-19 has more severe clinical presentations
and outcome in elderly males [19,20]. On the other hand,
plasma VWF levels are 20%–30% lower in normal blood
group O individuals compared to non-O subjects [21].
Since FVIII circulates in high-afﬁnity complex with VWF,
plasma FVIII levels are also reduced in blood group O
individuals. The reduced risk of COVID-19 induced
coagulopathy, due to the lower level of FVIII/VWF in
O BG patients, may be another hypothesis that could
explain the positive clinical course [22]. In our study,
when we compared the outcome of patients who received
CP containing anti-A Ab to the outcome of patients who
received CP not containing anti-A Ab, the duration in
the ICU was shorter and the rates of MV support and
VP support and CFR and discharge rates were lower in
patients who received CP containing anti-A Ab. However,
only the difference in the rate of MV support achieved

5 (38.5%)
5 (38.5)
2 (15.4%)
0
1 (7.7%)
1 (7.7%)
0

P value

CFR: case fatality rate; ICU: intensive care unit; MV: mechanical
ventilation; VP: vasopressor support; SD: standard deviation.

statistical significance. Although there are studies in
the literature examining the predictive effect of BGs on
COVID-19 patients, there is no study investigating this
relationship in critically ill COVID-19 patients receiving
CP. The opinion that Focosi stated in his letter that CP
containing high titer anti-A isoagglutinin may be more
effective in CP treatment supports the results of our study
[23]. Studies are ongoing to evaluate the correlations
between isoagglutinin titers and the outcome in BG 0 and
B patients.
The limitation of this study is that the number of
patients is insufficient to demonstrate the statistical effect
of CP on clinical results. If the number of cases were
higher, visible results would be statistically significant.
In conclusion, this study shows that treatment with
anti-A Ab containing CP may be more effective due to the
mechanism of blocking ACE2 receptors with the anti-A
Ab. Therefore, it may be more beneficial to choose the
O and B blood group donors/patients and titrate anti-A
isoagglutinins in the treatment of ABO blood groupcompatible CP in COVID-19 patients. Larger prospective
multicenter studies may be needed to demonstrate the
preventive and therapeutic role of Anti-A Ab.
Funding source: No funding was secured for this study.
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